Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

297 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Antiviral cellular therapy for enhancing T-cell reconstitution before or after hematopoietic stem cell transplantation (ACES): a two-arm, open label phase II interventional trial of pediatric patients with risk factor assessment.
Keller MD, Hanley PJ, Chi YY, Aguayo-Hiraldo P, Dvorak CC, Verneris MR, Kohn DB, Pai SY, Dávila Saldaña BJ, Hanisch B, Quigg TC, Adams RH, Dahlberg A, Chandrakasan S, Hasan H, Malvar J, Jensen-Wachspress MA, Lazarski CA, Sani G, Idso JM, Lang H, Chansky P, McCann CD, Tanna J, Abraham AA, Webb JL, Shibli A, Keating AK, Satwani P, Muranski P, Hall E, Eckrich MJ, Shereck E, Miller H, Mamcarz E, Agarwal R, De Oliveira SN, Vander Lugt MT, Ebens CL, Aquino VM, Bednarski JJ, Chu J, Parikh S, Whangbo J, Lionakis M, Zambidis ET, Gourdine E, Bollard CM, Pulsipher MA. Keller MD, et al. Among authors: dahlberg a. Nat Commun. 2024 Apr 18;15(1):3258. doi: 10.1038/s41467-024-47057-2. Nat Commun. 2024. PMID: 38637498 Free PMC article. Clinical Trial.
The influence of stem cell source on transplant outcomes for pediatric patients with acute myeloid leukemia.
Keating AK, Langenhorst J, Wagner JE, Page KM, Veys P, Wynn RF, Stefanski H, Elfeky R, Giller R, Mitchell R, Milano F, O'Brien TA, Dahlberg A, Delaney C, Kurtzberg J, Verneris MR, Boelens JJ. Keating AK, et al. Among authors: dahlberg a. Blood Adv. 2019 Apr 9;3(7):1118-1128. doi: 10.1182/bloodadvances.2018025908. Blood Adv. 2019. PMID: 30952678 Free PMC article.
Outcomes of pediatric patients with therapy-related myeloid neoplasms.
Sharma A, Huang S, Li Y, Brooke RJ, Ahmed I, Allewelt HB, Amrolia P, Bertaina A, Bhatt NS, Bierings MB, Bies J, Brisset C, Brondon JE, Dahlberg A, Dalle JH, Eissa H, Fahd M, Gassas A, Gloude NJ, Goebel WS, Goeckerman ES, Harris K, Ho R, Hudspeth MP, Huo JS, Jacobsohn D, Kasow KA, Katsanis E, Kaviany S, Keating AK, Kernan NA, Ktena YP, Lauhan CR, López-Hernandez G, Martin PL, Myers KC, Naik S, Olaya-Vargas A, Onishi T, Radhi M, Ramachandran S, Ramos K, Rangarajan HG, Roehrs PA, Sampson ME, Shaw PJ, Skiles JL, Somers K, Symons HJ, de Tersant M, Uber AN, Versluys B, Cheng C, Triplett BM. Sharma A, et al. Among authors: dahlberg a. Bone Marrow Transplant. 2021 Dec;56(12):2997-3007. doi: 10.1038/s41409-021-01448-x. Epub 2021 Sep 3. Bone Marrow Transplant. 2021. PMID: 34480120 Free PMC article.
HA-1-targeted T cell receptor (TCR) T cell therapy for recurrent leukemia after hematopoietic stem cell transplantation.
Krakow EF, Brault M, Summers C, Cunningham TM, Biernacki MA, Black RG, Woodward KB, Vartanian N, Kanaan SB, Yeh AC, Dossa RG, Bar M, Cassaday RD, Dahlberg A, Till BG, Denker AE, Yeung CCS, Gooley TA, Maloney DG, Riddell SR, Greenberg PD, Chapuis AG, Newell EW, Furlan SN, Bleakley M. Krakow EF, et al. Among authors: dahlberg a. Blood. 2024 Apr 29:blood.2024024105. doi: 10.1182/blood.2024024105. Online ahead of print. Blood. 2024. PMID: 38683966
Cord-Blood Transplantation in Patients with Minimal Residual Disease.
Milano F, Gooley T, Wood B, Woolfrey A, Flowers ME, Doney K, Witherspoon R, Mielcarek M, Deeg JH, Sorror M, Dahlberg A, Sandmaier BM, Salit R, Petersdorf E, Appelbaum FR, Delaney C. Milano F, et al. Among authors: dahlberg a. N Engl J Med. 2016 Sep 8;375(10):944-53. doi: 10.1056/NEJMoa1602074. N Engl J Med. 2016. PMID: 27602666 Free PMC article. Clinical Trial.
Risk Factors for Subsequent Central Nervous System Tumors in Pediatric Allogeneic Hematopoietic Cell Transplant: A Study from the Center for International Blood and Marrow Transplant Research (CIBMTR).
Gabriel M, Shaw BE, Brazauskas R, Chen M, Margolis DA, Sengelov H, Dahlberg A, Ahmed IA, Delgado D, Lazarus HM, Gibson B, Myers KC, Kamble RT, Abdel-Mageed A, Li CK, Flowers MED, Battiwalla M, Savani BN, Majhail N, Shaw PJ. Gabriel M, et al. Among authors: dahlberg a. Biol Blood Marrow Transplant. 2017 Aug;23(8):1320-1326. doi: 10.1016/j.bbmt.2017.04.004. Epub 2017 Apr 12. Biol Blood Marrow Transplant. 2017. PMID: 28411175 Free PMC article. Clinical Trial.
Guidelines for Pediatric Unrelated Cord Blood Transplantation-Unique Considerations.
Dahlberg A, Kurtzberg J, Boelens J, Martinez C, Carpenter P, Tewari P; American Society for Transplantation and Cellular Therapy Cord Blood Special Interest Group. Dahlberg A, et al. Transplant Cell Ther. 2021 Dec;27(12):968-972. doi: 10.1016/j.jtct.2021.09.013. Epub 2021 Sep 24. Transplant Cell Ther. 2021. PMID: 34571212 Free article. Review.
Hematopoietic Cell Transplantation after CD19 Chimeric Antigen Receptor T Cell-Induced Acute Lymphoblastic Lymphoma Remission Confers a Leukemia-Free Survival Advantage.
Summers C, Wu QV, Annesley C, Bleakley M, Dahlberg A, Narayanaswamy P, Huang W, Voutsinas J, Brand A, Leisenring W, Jensen MC, Park JR, Gardner RA. Summers C, et al. Among authors: dahlberg a. Transplant Cell Ther. 2022 Jan;28(1):21-29. doi: 10.1016/j.jtct.2021.10.003. Epub 2021 Oct 10. Transplant Cell Ther. 2022. PMID: 34644605 Free article. Clinical Trial.
297 results